Jazz Pharmaceuticals

markets Epidiolex, the FDA-approved plant-derived CBD drug for severe childhood epilepsy, reporting 15% year-on-year sales growth in Q1 2026 as part of 19% overall company revenue growth.

Country
Ireland
Ticker
JAZZ
pharma eu
Coverage
CNEUUS
specialty-fine-chem✓✓✓
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Revenue$250 million in Epidiolex/Epidyolex net product sales in Q1 2026, a 15% increase year-on-yearfinance.yahoo.com · investor.jazzpharma.com · sec.gov
Revenue$1.1 billion total revenue in Q1 2026, a 19% increase year-on-yearfinance.yahoo.com · investor.jazzpharma.com · sec.gov
Revenue$292.1 million in Epidiolex/Epidyolex net product sales in Q2 2026, a 16% increase year-on-yearinvestor.jazzpharma.com
Revenue$1.2083 billion total revenue in Q2 2026investor.jazzpharma.com
Production siteManufacturing and development facility in Athlone, Ireland; manufacturing facility in Kent Science Park, U.K.; manufacturing plant in Villa Guardia, Italyjazzpharma.com
Regulatory approvalFDA-approved for treatment of seizures associated with LGS, DS, and TSC in patients 1 year of age and older; approved in other international markets including Europe, U.K., Canada, Israel, Australia, Switzerland, Taiwan, and New Zealandinvestor.jazzpharma.com · epidiolex.com · marketscreener.com
CertificationInternal manufacturing sites certified under ISO 45001 and ISO 14001:2015 standardsjazzpharma.com

Independent sources: epidiolex.com · finance.yahoo.com · investor.jazzpharma.com · marketscreener.com · sec.gov

Technologies
NameClusterRisk
Biosynthetic cannabinoids (CBD & THC)specialty-fine-chemMedium→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.